Key Takeaways:
The U.S. Food and Drug Administration approved Takeda's rusfertide (MIMRYLO) on Friday for polycythemia vera, a rare blood cancer affecting roughly 90,000 Americans.
"Current treatments, such as phlebotomy, leave a significant gap for too many patients and can pose challenges to daily life and routines," Andrew T. Kuykendall, VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center, said.
The approval was supported by the global Phase 3 VERIFY trial, in which 76.9 percent of patients receiving rusfertide plus standard of care achieved a clinical response versus 32.9 percent on placebo (P<.0001). Patients on the drug needed a mean 0.5 phlebotomies versus 1.8 on placebo, and 62.6 percent maintained hematocrit below 45 percent versus 14.4 percent.
Takeda projects peak global sales of $1 billion to $2 billion. The drug will be available within 48 hours of approval, Teresa Bitetti, president of Takeda's global oncology business unit, said.
Polycythemia vera causes the bone marrow to overproduce red blood cells, thickening the blood and sharply raising the risk of life-threatening clots, strokes and heart attacks. For decades, treatment has relied on therapeutic phlebotomy, a procedure that involves regularly removing blood to keep red blood cell levels under control. An estimated 78 percent of patients still experience uncontrolled hematocrit with current standard of care, and those patients face a four times higher risk of cardiovascular death or major cardiovascular events.
Rusfertide works by mimicking hepcidin, the body's master iron-regulating hormone, to restrict iron availability and prevent the bone marrow from overproducing red blood cells. It is administered once weekly via subcutaneous injection. The most common adverse reactions were injection site reactions (56 percent) and anemia (16 percent).
Takeda secured the global rights to co-develop and commercialize the drug from its developer Protagonist Therapeutics through a 2024 licensing agreement. Protagonist discovered rusfertide and led its development through Phase 3.
At 52 weeks in the VERIFY trial, 61.9 percent of patients on rusfertide had an enduring clinical response, and 84.1 percent of those who responded during weeks 20 to 32 sustained that response. Among patients who crossed over from placebo to rusfertide at week 32, 77.9 percent achieved a clinical response. In the long-term THRIVE extension, the mean annualized phlebotomy rate fell from 9.2 per year at baseline to 0.7 per year.
The approval gives Takeda a first-in-class therapy in a disease where roughly 90,000 Americans have long relied on burdensome blood draws, a drug that could become a new standard of care. Investors will watch the launch trajectory and pricing decisions, as well as regulatory reviews outside the U.S., where Takeda is working to bring MIMRYLO to more patients.
This article is for informational purposes only and does not constitute investment advice.
